People dispensed a strong opioid medicine one or more times in a year

Description

This indicator shows the number and rate per 1,000 of the PHO-enrolled population who had a strong opioid dispensed to them by a community pharmacy, by year (2019 to 2023), ethnic group, age group and gender.

Rationale

The Institute for Healthcare Improvement (IHI) classifies opioids as one of four groups of medicines (along with anticoagulants, insulin and sedatives) that can cause harm to patients, even when used as intended. 

Measure set
Health areas and conditions
Notes about this measure set
A ‘strong’ opioid is classed as step 3 of the World Health Organization’s (WHO) analgesic ladder. This includes fentanyl, methadone, morphine, oxycodone and pethidine. These opioids are subsidised in New Zealand. 
Measure type
Count
Other
Numerator

PHO-enrolled population who were dispensed a strong opioid: morphine, fentanyl, methadone (excluding those using for substance abuse), oxycodone and pethidine during the calendar year.

Numerator detail

Medications: 1274 Fentanyl citrate; 1795 Methadone hydrochloride; 1830 Morphine hydrochloride; 1831 Morphine sulphate; 2383 Morphine tartrate; 3801 Fentanyl; 3822 Oxycodone hydrochloride; 3896 Fentanyl citrate; 1953 Pethidine hydrochloride

Numerator exclusions

Opioid substitution treatment was excluded by identifying people who had methadone dispensed every one, two or three days. People who met this criterion were excluded from further analysis. Note that individuals are excluded if they were dispensed methadone in this pattern at any time prior to or during the year of interest. This method may incorrectly exclude people who had this pattern of dispensing for a different reason, however, a comparison between the number of people registered with the Ministry of Health as receiving opioid substitution treatment and the number of people excluded suggests this method is sufficiently accurate.  

Denominator

PHO-enrolled population during the calendar year 

Disaggregation

District analysis: By year (2019 –2023), age group (0–24, 25–64; 65–79 and 80 and over), gender (female, male), ethnic group (Māori, Pacific peoples, Asian and European/Other) and Health New Zealand district of domicile. 

PHO analysis: By year (2023), age group, gender, ethnic group, Primary Health Organisation (PHO) most recently enrolled with (for the relevant year), PHO group (small, medium, medium-large and large). 

Notes

People who were excluded from the analysis were:

  • individuals with missing demographics– that is, those with no recorded value for one or more of the National Health Index (NHI) fields used to derive the demographic variables of interest (age, gender, ethnicity and district of domicile). For instance, a person with no recorded ethnicity in 2023 is excluded from all indicators for that calendar year. This approach ensures a consistent denominator throughout the analyses.
  • those who weren’t enrolled in a PHO in the calendar year. 

Data is not presented where the number of people in the numerator was less than 10. This is to preserve confidentiality. 

Age group is assigned using 30 June of each calendar year as the cutoff point. For example, a person turning 65 years old on 30 June 2023 will be assigned to the 65–79 years age group for 2023, while a person turning 65 on 1 July 2023 will be assigned the 25–64 group for the same year.. 

Unlike other atlases, the Opioid Atlas includes individuals who died during the calendar year in all indicators. This is because opioid use is higher among older adults and those in the final stages of life, due to chronic conditions, pain management, and palliative care needs. Including them ensures a complete and accurate picture of opioid exposure.

 

See technical document for details

Measure methodology last updated
November 2025
Reference period
2019-2023